Developed through a collaboration between
OVERVIEW
The treatment landscape of B-cell malignancies continues to evolve, with new and novel drugs being investigated and added to the armamentarium. Since their introduction, Bruton tyrosine kinase (BTK) inhibitors have dramatically changed the treatment of B-cell malignancies, emerging as one of the backbones of treatment. The high anti-lymphoma activity of BTK inhibitors has led to approvals to treat chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).
Join our multidisciplinary panel of experts, including hematologists, a specialist nurse, and a patient advocate, as they guide us in an interactive discussion on the role of BTK inhibitors in treating B-cell malignancies - how BTK inhibitors fit into the treatment landscape and the clinical evidence supporting their use. The panel will also explore patient perspectives in the management of their disease using BTK inhibitors, with emphasis on the needs of the patient, and the importance of meeting their treatment goals.
Enhance Your Virtual Experience With Backstage Pass!
Join our 30-minute post-symposium breakout session connecting the program speakers and audience in the virtual environment. Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.
*Video Encouraged*
GOAL STATEMENT
The goal of this activity is that learners will be better able to use BTK inhibitors for the individual patient with B-cell malignancies.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST][ITEM]Latest clinical data with BTK inhibitors for B-cell malignancies [ITEM]Factors informing treatment decisions with BTK inhibitors for B-cell malignancies [/LIST]Have greater competence related to [LIST][ITEM]Using BTK inhibitors to manage patients with B-cell malignancies [/LIST]Demonstrate greater confidence in their ability to [LIST][ITEM]Integrate the latest data with BTK inhibitors into the management of patients with B-cell malignancies [/LIST]
ACCREDITATION STATEMENT
[WEBMDGLOBAL] The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.5 continuing professional development credits (CPD).
Supported by an independent educational grant from [BOLD]BeiGene[/BOLD]